Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2003 3
2004 5
2005 1
2008 1
2010 4
2011 1
2012 1
2019 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
Gale DD, Hofer P, Spina D, Seeds EA, Banner KH, Harrison S, Douglas G, Matsumoto T, Page CP, Wong RH, Jordan S, Smith F, Banik N, Halushka PV, Cavalla D, Rotshteyn Y, Kyle DJ, Burch RM, Chasin M. Gale DD, et al. Among authors: rotshteyn y. Pulm Pharmacol Ther. 2003;16(2):97-104. doi: 10.1016/S1094-5539(02)00175-X. Pulm Pharmacol Ther. 2003. PMID: 12670778 Review.
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
Sun Q, Tafesse L, Islam K, Zhou X, Victory SF, Zhang C, Hachicha M, Schmid LA, Patel A, Rotshteyn Y, Valenzano KJ, Kyle DJ. Sun Q, et al. Among authors: rotshteyn y. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3611-6. doi: 10.1016/s0960-894x(03)00759-5. Bioorg Med Chem Lett. 2003. PMID: 14505681
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Petrylak DP, Kantoff P, Vogelzang NJ, Mega A, Fleming MT, Stephenson JJ Jr, Frank R, Shore ND, Dreicer R, McClay EF, Berry WR, Agarwal M, DiPippo VA, Rotshteyn Y, Stambler N, Olson WC, Morris SA, Israel RJ. Petrylak DP, et al. Among authors: rotshteyn y. Prostate. 2019 May;79(6):604-613. doi: 10.1002/pros.23765. Epub 2019 Jan 20. Prostate. 2019. PMID: 30663074 Clinical Trial.
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.
Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC. Jacobson JM, et al. Among authors: rotshteyn y. Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26. Antimicrob Agents Chemother. 2010. PMID: 20660677 Free PMC article. Clinical Trial.
Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans.
Chandrasekaran A, Tong Z, Li H, Erve JC, DeMaio W, Goljer I, McConnell O, Rotshteyn Y, Hultin T, Talaat R, Scatina J. Chandrasekaran A, et al. Among authors: rotshteyn y. Drug Metab Dispos. 2010 Apr;38(4):606-16. doi: 10.1124/dmd.109.031179. Epub 2010 Jan 6. Drug Metab Dispos. 2010. PMID: 20053817 Clinical Trial.
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC. Jacobson JM, et al. Among authors: rotshteyn y. J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169. J Infect Dis. 2008. PMID: 18771406 Clinical Trial.
19 results